Cardiac and vascular effects of cannabinoids: Toward a therapeutic use?;Effets cardiaques et vasculaires des cannabinoïdes: Vers une utilisation thérapeutique en cardiologie?

Annales de Cardiologie et d'Angeiologie

Volumn 54, Issue 2, 2005, Pages 89-96

  Ribuot, C ^a   Lamontagne, D ^b   Godin Ribuot, D ^a  

^a University Grenoble Alpes   (France)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Cannabinoids; Preconditioning; Vascular reactivity

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ANANDAMIDE; CANNABIDIOL; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CANNABINOL; DEXANABINOL; DOPAMINE DERIVATIVE; DRONABINOL; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; NOLADINE; OLEAMIDE; RIMONABANT; UNCLASSIFIED DRUG; VIRODHAMINE;

ARTICLE; BLEEDING; BRAIN ISCHEMIA; CARDIOVASCULAR EFFECT; CARDIOVASCULAR SYSTEM; HEART INFARCTION; HEART MUSCLE ISCHEMIA; REPERFUSION INJURY; SEPTIC SHOCK;

EID: 15544365473     PISSN: 00033928     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ancard.2004.11.011     Document Type: Article

References (80)

1. Devane W. A., Dysarz F. A., 3rd, Johnson M. R., Melvin L. S., and Howlett A. C. (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34, 605-613.
2. Devane W. A., Hanus L., Breuer A., Pertwee R. G., Stevenson L. A., Griffin G., et al. (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946-1949.
3. Munro S., Thomas K. L., and Abu-Shaar M. (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61-65.
4. Herkenham M., Lynn A. B., Little M. D., Johnson M. R., Melvin L. S., de Costa B. R., and Rice, K. C. (1990) Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 87, 1932-1936.
5. Hogestatt E. D., and Zygmunt P. M. (2002) Cardiovascular pharmacology of anandamide. Prostaglandins Leukot Essent Fatty Acids 66, 343-351.
6. Kunos, G., Batkai, S., Offertaler, L., Mo, F., Liu, J., Karcher, J., and Harvey-White, J. (2002) The quest for a vascular endothelial cannabinoid receptor. Chem Phys Lipids 121, 45-56.
7. Galiegue S., Mary S., Marchand J., Dussossoy D., Carriere D., Carayon P., et al. (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232, 54-61.
8. Vollmer R. R., Cavero I., Ertel R. J., Solomon T. A., and Buckley J. P. (1974) Role of the central autonomic nervous system in the hypotension and bradycardia induced by (-)-delta 9-trans-tetrahydrocannabinol. J Pharm Pharmacol 26, 186-192.
9. Varga K., Lake K., Martin B. R., and Kunos G. (1995) Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. Eur J Pharmacol 278, 279-283.
10. Jarai Z., Wagner J. A., Goparaju S. K., Wang L., Razdan, R. K., Sugiura Tet al. (2000) Cardiovascular effects of 2-arachidonoyl glycerol in anesthetized mice. Hypertension 35, 679-684.
11. Lepicier P., Bouchard J. F., Lagneux C., and Lamontagne D. (2003) Endocannabinoids protect the rat isolated heart against ischaemia. Br J Pharmacol 139, 805-815.
12. Bouchard J. F., Lepicier P., and Lamontagne D. (2003) Contribution of endocannabinoids in the endothelial protection afforded by ischemic preconditioning in the isolated rat heart. Life Sci 72, 1859-1870.
13. Lagneux C., and Lamontagne D. (2001) Involvement of cannabinoids in the cardioprotection induced by lipopolysaccharide. Br J Pharmacol 132, 793-796.
14. Joyeux M., Arnaud C., Godin-Ribuot D., Demenge P., Lamontagne D., and Ribuot C. (2002) Endocannabinoids are implicated in the infarct size-reducing effect conferred by heat stress preconditioning in isolated rat hearts. Cardiovasc Res 55, 619-625.
15. Petrocellis L. D., Cascio M. G., and Marzo V. D. (2004) The endocannabinoid system: a general view and latest additions. Br J Pharmacol 141, 765-774.
16. Leggett J. D., Aspley S., Beckett S. R., D'Antona A. M., and Kendall D. A. (2004) Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors. Br J Pharmacol 141, 253-262.
17. Howlett, A. C., Barth F., Bonner T. I., Cabral G., Casellas P., Devane W. A., et al. (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54, 161-202.
18. Yellon D. M., and Downey J. M. (2003) Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev 83, 1113-1151
19. Felder, C. C., and Glass, M. (1998) Cannabinoid receptors and their endogenous agonists. Annu Rev Pharmacol Toxicol 38, 179-200.
20. Jarai Z., Wagner J. A., Varga K., Lake K. D., Compton D. R., Martin B. R., et al. (1999) Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci U S A 96, 14136-14141.
21. Hu C. P., Li N. S., Peng J., Xiao L., Deng H. W., and Li Y. J. (2003) Involvement of vanilloid receptors in heat stress-induced delayed protection against myocardial ischemia-reperfusion injury. Neuropeptides 37, 233-238.
22. Hillard C. J., and Auchampach J. A. (1994) In vitro activation of brain protein kinase C by the cannabinoids. Biochim Biophys Acta 1220, 163-170.
23. Ytrehus K., Liu Y., and Downey J. M. (1994) Preconditioning protects ischemic rabbit heart by protein kinase C activation. Am J Physiol 266, H1145-H1152.
24. Joyeux M., Baxter G. F., Thomas D. L., Ribuot, C., and Yellon, D. M. (1997) Protein kinase C is involved in resistance to myocardial infarction induced by heat stress. J Mol Cell Cardiol 29, 3311-3319.
25. Beauchamp, P., Richard, V., Tamion, F., Lallemand, F., Lebreton, J. P., Vaudry, H., Daveau, M., and Thuillez, C. (1999) Protective effects of preconditioning in cultured rat endothelial cells: effects on neutrophil adhesion and expression of ICAM-1 after anoxia and reoxygenation. Circulation 100, 541-546.
26. Ho B. Y., Uezono Y., Takada, S., Takase, I., and Izumi, F. (1999) Coupling of the expressed cannabinoid CB1 and CB2 receptors to phospholipase C and G protein-coupled inwardly rectifying K+ channels. Receptors Channels 6, 363-374.
27. Mukhopadhyay S., Shim J. Y., Assi A. A., Norford, D., and Howlett A. C. (2002) CB(1) cannabinoid receptor-G protein association: a possible mechanism for differential signaling. Chem Phys Lipids 121, 91-109.
28. Lagneux C., Adam A., and Lamontagne D. (2003) A study of the mediators involved in the protection induced by exogenous kinins in the isolated rat heart. Int Immunopharmacol 3, 1511-1518.
29. Di Filippo C., Rossi F., Rossi S., and D'Amico M. (2003) Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: involvement of cytokine/chemokines and PMN. J Leukoc Biol
30. Wagner J. A., Hu K., Karcher J., Bauersachs J., Schafer A., Laser M., et al. (2003) CB(1) cannabinoid receptor antagonism promotes remodeling and cannabinoid treatment prevents endothelial dysfunction and hypotension in rats with myocardial infarction. Br J Pharmacol 138, 1251-1258.
31. Hiley C. R., and Ford W. R. (2003) Endocannabinoids as mediators in the heart: a potential target for therapy of remodelling after myocardial infarction? Br J Pharmacol 138, 1183-1184.
32. Mittleman M. A., Lewis R. A., Maclure M., Sherwood J. B., and Muller J. E. (2001) Triggering myocardial infarction by marijuana. Circulation 103, 2805-2809.
33. Varga K., Lake K. D., Huangfu D., Guyenet P. G., and Kunos G. (1996) Mechanism of the hypotensive action of anandamide in anesthetized rats. Hypertension 28, 682-686.
34. Lake K. D., Martin B. R., Kunos G., and Varga K. (1997) Cardiovascular effects of anandamide in anesthetized and conscious normotensive and hypertensive rats. Hypertension 29, 1204-1210.
35. Randall M. D., Harris D., Kendall D. A., and Ralevic V. (2002) Cardiovascular effects of cannabinoids. Pharmacol Ther 95, 191-202.
36. Gebremedhin D., Lange A. R., Campbell W. B., Hillard C. J., and Harder D. R. (1999) Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current. Am J Physiol 276, H2085-H2093.
37. Wagner J. A., Jarai Z., Batkai S., and Kunos G. (2001) Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors. Eur J Pharmacol 423, 203-210.
38. Randall M. D., and Kendall D. A. (1997) Involvement of a cannabinoid in endothelium-derived hyperpolarizing factor-mediated coronary vasorelaxation. Eur J Pharmacol 335, 205-209.
39. Bilfinger T. V., Salzet M., Fimiani C., Deutsch D. G., Tramu G., and Stefano G. B. (1998) Pharmacological evidence for anandamide amidase in human cardiac and vascular tissues. Int J Cardiol 64 Suppl 1, S15-S22.
40. Fleming I., Schermer B., Popp R., and Busse R. (1999) Inhibition the production of endothelium-derived hyperpolarizing factor cannabinoid receptor agonists. Br J Pharmacol 126, 949-960.
41. Chaytor A. T., Martin P. E., Evans W. H., Randall M. D., and Griffith T. M. (1999) The endothelial component of cannabinoid-induced relaxation in rabbit mesenteric artery depends on gap junctional communication. J Physiol 520 Pt 2, 539-550.
42. White, R., and Hiley, C. R. (1997) A comparison of EDHF-mediated and anandamide-induced relaxations in the rat isolated mesenteric artery. Br J Pharmacol 122, 1573-1584.
43. Zygmunt P. M., Petersson J., Andersson D. A., Chuang H., Sorgard M., Di Marzo V, et al. (1999) Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400, 452-457.
44. Gardiner S. M., March J. E., Kemp P. A., and Bennett T. (2001) Regional haemodynamic responses to the cannabinoid agonist, WIN 55212-2, in conscious, normotensive rats, and in hypertensive, transgenic rats. Br J Pharmacol 133, 445-453.
45. Benowitz N. L., and Jones R. T. (1977) Prolonged delta- tetrahydrocannabinol ingestion. Effects of sympathomimetic amines and autonomic blockades. Clin Pharmacol Ther 21, 336-342.
46. Pars H. G., and Howes J. F. (1977) Potential therapeutic agents derived from the cannabinoid nucleus. Adv Drug Res 11, 97-189.
47. Benowitz N. L., and Jones R. T. (1975) Cardiovascular effects prolonged delta-9-tetrahydrocannabinol ingestion. Clin Pharmacol Ther 18, 287-297.
48. Kanakis C., Jr., Pouget J. M., and Rosen K. M. (1976) The effects delta-9-tetrahydrocannabinol (cannabis) on cardiac performance with and without beta blockade. Circulation 53, 703-707.
49. Jandhyala B. S. (1978) Effects of prolonged administration of delta 9-tetrahydrocannabinol on the autonomic and cardiovascular function and regional hemodynamics in mongrel dogs. Res Commun Chem Pathol Pharmacol 20, 489-508.
50. Ellis E. F., Moore S. F., and Willoughby K. A. (1995) Anandamide and delta 9-THC dilation of cerebral arterioles is blocked indomethacin. Am J Physiol 269, H1859-H1864.
51. Jandhyala B. S., Malloy K. P., and Buckley J. P. (1976) Effects acute administration of delta9-tetrahydrocannabinol on pulmonary hemodynamics of anesthetized dogs. Eur J Pharmacol 38, 183-187.
52. Randall M. D., Alexander S. P., Bennett T., Boyd E. A., Fry J. Gardiner S. M., et al. (1996) An endogenous cannabinoid as endothelium-derived vasorelaxant. Biochem Biophys Res Commun 229, 114-120.
53. Randall M. D., McCulloch A. I., and Kendall D. A. (1997) Comparative pharmacology of endothelium-derived hyperpolarizing factor and anandamide in rat isolated mesentery. Eur J Pharmacol 333, 191-197.
54. Plane F., Holland M., Waldron G. J., Garland C. J., and Boyle J. (1997) Evidence that anandamide and EDHF act via different mechanisms in rat isolated mesenteric arteries. Br J Pharmacol 121, 1509-1511.
55. Pratt P F., Hillard C. J., Edgemond W. S., and Campbell W. B. (1998) N-arachidonylethanolamide relaxation of bovine coronary artery is not mediated by CB1 cannabinoid receptor. Am J Physiol 274, H375-H381.
56. Wagner J. A., Varga K., Ellis E. F., Rzigalinski B. A., Martin B. and Kunos G. (1997) Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature 390, 518-521.
57. Cainazzo M. M., Ferrazza G., Mioni C., Bazzani C., Bertolini A., and Guarini S. (2002) Cannabinoid CB(1) receptor blockade enhances the protective effect of melanocortins in hemorrhagic shock in the rat. Eur J Pharmacol 441, 91-97.
58. Varga, K., Wagner, J. A., Bridgen, D. T., and Kunos, G. (1998) Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. Faseb J 12, 1035-1044.
59. Maccarrone, M., Bari, M., Battista, N., and Finazzi-Agro, A. (2002) Endocannabinoid degradation, endotoxic shock and inflammation. Curr Drug Targets Inflamm Allergy 1, 53-63.
60. Wang Y., Liu Y., Ito Y., Hashiguchi T., Kitajima I., Yamakuchi M., et al. (2001) Simultaneous measurement of anandamide and 2-arachidonoylglycerol by polymyxin B-selective adsorption and subsequent high-performance liquid chromatography analysis: increase in endogenous cannabinoids in the sera of patients with endotoxic shock. Anal Biochem 294, 73-82.
61. Grundy R. I. (2002) The therapeutic potential of the cannabinoids in neuroprotection. Expert Opin Investig Drugs 11, 1365-1374.
62. Croxford J. L. (2003) Therapeutic potential of cannabinoids in CNS disease. CNS Drugs 17, 179-202.
63. Gerard C. M., Mollereau C., Vassart G., and Parmentier M. (1991) Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J 279 ( Pt 1), 129-134.
64. Bayewitch M., Rhee M. H., Avidor-Reiss T., Breuer A., Mechoulam R., and Vogel Z. (1996) (-)-Delta9-tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase. J Biol Chem 271, 9902-9905.
65. Rhee M. H., Vogel Z., Barg J., Bayewitch M., Levy R., Hanus L., et al. (1997) Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase. J Med Chem 40, 3228-3233.
66. Condie R., Herring A., Koh W. S., Lee M., and Kaminski N. E. (1996) Cannabinoid inhibition of adenylate cyclase-mediated signal transduction and interleukin 2 (IL-2) expression in the murine T-cell line, EL4.IL-2. J Biol Chem 271, 13175-13183.
67. Showalter V. M., Compton D. R., Martin B. R., and Abood M. E. (1996) Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 278, 989-999.
68. Bayewitch M., Avidor-Reiss T., Levy R., Barg J., Mechoulam R., and Vogel Z. (1995) The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. FEBS Lett 375, 143-147.
69. Rinaldi-Carmona M., Pialot F., Congy C., Redon E., Barth F., Bachy A et al.. (1996) Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain. Life Sci 58, 1239-1247.
70. Stella N., Schweitzer P., and Piomelli D. (1997) A second endogenous cannabinoid that modulates long-term potentiation. Nature 388, 773-778.
71. Sugiura T., Kondo S., Kishimoto S., Miyashita T., Nakane S., Kodaka T., et al. (2000) Evidence that 2-arachidonoylglycerol but not N- palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J Biol Chem 275, 605-612.
72. Bisogno T., Melck D., Bobrov M., Gretskaya N. M., Bezuglov V. V., De Petrocellis L., et al. (2000) N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem J 351 Pt 3, 817-824.
73. Hanus L., Abu-Lafi S., Fride E., Breuer A., Vogel Z., Shalev D. E., et al. (2001) 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A 98, 3662-3665.
74. Porter A. C., Sauer J. M., Knierman M. D., Becker G. W., Berna M. J., Bao, J., et al. (2002) Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 301, 1020-1024.
75. Slipetz D. M., O'Neill G. P., Favreau L., Dufresne C., Gallant M., Gareau Yet al. (1995) Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase. Mol Pharmacol 48, 352-361.
76. Song Z. H., and Bonner T. I. (1996) A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2. Mol Pharmacol 49, 891-896.
77. Tao Q., and Abood M. E. (1998) Mutation of a highly conserved aspartate residue in the second transmembrane domain of the cannabinoid receptors, CB1 and CB2, disrupts G-protein coupling. J Pharmacol Exp Ther 285, 651-658.
78. Rinaldi-Carmona M., Le Duigou A., Oustric D., Barth F., Bouaboula M., Carayon P, et al.. (1998) Modulation of CB1 cannabinoid receptor functions after a long-term exposure to agonist or inverse agonist in the Chinese hamster ovary cell expression system. J Pharmacol Exp Ther 287, 1038-1047.
79. Rinaldi-Carmona M., Barth F., Heaulme M., Shire D., Calandra B., Congy C. et al. (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350, 240-244.
80. Fowler C. J. (2004) Oleamide: a member of the endocannabinoid family? Br J Pharmacol 141, 195-196.